RBC Capital Reaffirms Their Buy Rating on Zimmer Biomet Holdings (ZBH)

Barclays initiated coverage on 26 medical device makers, rating Stryker (SYK) and Abbott Laboratories (ABT) as Overweight. Analyst Christopher Pasquale cited compelling valuations and a potential stabilization of revenue as catalysts. Price targets were set for several companies, including SYK at $375 and ABT at $120.

Zimmer Biomet (ZBH) reported Q2 results on Aug. 5, with adjusted EPS of $2.07 vs $2.01 expected and revenue of $2.2B vs $2.1B forecast. The company guided full-year adjusted EPS to $8.47-$8.59. Analysts covering ZBH have a Hold consensus, with a mean price target of $104.67 and a Street-high of $125.

Zimmer Biomet reported Q2 2026 organic constant-currency revenue growth of 4%, led by a 4.6% U.S. increase and 3.1% international growth. Management raised full-year organic guidance to 2.25%-3.25% and adjusted EPS to $8.47-$8.59, including $1B planned 2026 share repurchases. China revenue fell 20%.

Zimmer Biomet (NYSE:ZBH) reported Q2 adjusted EPS of $2.07, above the $2.01 consensus, and revenue of $2.18B, up 4.8% year over year and above the $2.14B estimate. The company raised FY2026 guidance to $8.47-$8.59 adjusted EPS and 3.9%-4.9% reported sales growth, and expects up to $1B in share repurchases.

Zimmer Biomet reported Q2 revenue of about $2.18bn, up 4.8% YoY. Knees led at $828.9m, followed by S.E.T. at $586m and hips at $562.7m. The company raised its 2026 revenue growth outlook to 3.9% to 4.9% and adjusted EPS to $8.47 to $8.59 per diluted share. Shares rose over 5% to about $101 at the open.

Zimmer Biomet (ZBH) reported Q2 net earnings of $198.3 million, or $1.03 per share, versus $152.8 million, or $0.77 per share, a year earlier. Net sales rose to $2,177.0 million from $2,077.3 million. For FY2026, it raised reported revenue growth to 3.9% to 4.9% and adjusted EPS to $8.47 to $8.59. Shares were up pre-market to $100.15.